Efficacy and safety of cabazitaxel therapy in elderly (≥75 years) patients with castration-resistant prostate cancer: A multiinstitutional study

Shiota, 2016, Taxane Chemotherapy for Hormone-Naïve Prostate Cancer with Its Expanding Role as Breakthrough Strategy, Frontiers in Oncology, 5, 10.3389/fonc.2015.00304 Shiota, 2016, Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer, Int J Urol, 23, 360, 10.1111/iju.13091 Horgan, 2014, Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial, J Geriatric Oncology, 5, 119, 10.1016/j.jgo.2013.12.001 Droz, 2016, First-line treatment in senior adults with metastatic castration-resistant prostate cancer: A prospective international registry, Urol Oncol: Seminars and Original Investigations, 34, 234.e221, 10.1016/j.urolonc.2015.12.005 Sweeney, 2015, Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer, N Engl J Med, 373, 737, 10.1056/NEJMoa1503747 de Bono, 2010, Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial, Lancet, 376, 1147, 10.1016/S0140-6736(10)61389-X Nozawa, 2015, Japanese phase I study of cabazitaxel in metastatic castration-resistant prostate cancer, Int J Clin Oncol, 20, 1026, 10.1007/s10147-015-0820-9 Shigeta, 2015, Predictive factors for severe and febrile neutropenia during docetaxel chemotherapy for castration-resistant prostate cancer, Int J Clin Oncol, 20, 605, 10.1007/s10147-014-0746-7 Matsubara, 2020, Cabazitaxel in patients aged ≥80 years with castration-resistant prostate cancer: Results of a post-marketing surveillance study in Japan, J Geriatr Oncol, 11, 1067, 10.1016/j.jgo.2020.02.014 Shiota, 2020, Prognostic significance of lactate dehydrogenase in cabazitaxel chemotherapy for castration-resistant prostate cancer: a multi-institutional study, Anti Canc Drugs, 31, 298, 10.1097/CAD.0000000000000884 Shiota, 2020, Prognostic Impact of Prior Androgen Receptor Axis-targeting Agents in Cabazitaxel Chemotherapy After Docetaxel, Anticancer Res, 40, 335, 10.21873/anticanres.13957 Scher, 2008, Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group, J Clin Oncol, 26, 1148, 10.1200/JCO.2007.12.4487 Kanda, 2013, Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics, Bone Marrow Transplant, 48, 452, 10.1038/bmt.2012.244 Kosaka, 2018, No significant impact of patient age and prior treatment profile with docetaxel on the efficacy of cabazitaxel in patient with castration-resistant prostate cancer, Canc Chemother Pharmacol, 82, 1061, 10.1007/s00280-018-3698-1 Yamamoto, 2020, Safety and efficacy of cabazitaxel in Japanese patients with castration-resistant prostate cancer, Prostate International, 8, 27, 10.1016/j.prnil.2019.10.005 Heidenreich, 2014, Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: Results of the European compassionate-use programme, Eur J Canc, 50, 1090, 10.1016/j.ejca.2014.01.006